Nurix Therapeutics Inc Ordinary Shares NRIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
-
Roche Licenses Nurix Therapeutics Blood-Cancer Drug for Up to $2.3 Billion — Update
-
Nurix Therapeutics Shares Surge Premarket on Roche Deal
-
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
Trading Information
- Previous Close Price
- $23.34
- Day Range
- $22.85–23.75
- 52-Week Range
- $8.99–28.23
- Bid/Ask
- $22.78 / $23.50
- Shares Outstanding
- 103.78M
- Market Cap
- $2.39B
- Volume/Avg
- 815,509 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 63.54
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 357
- Website
- https://www.nurixtx.com
Valuation
|
Metric
|
NRIX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.01 |
Price/Sales | 63.54 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NRIX
|
|---|---|
Quick Ratio | 6.16 |
Current Ratio | 6.34 |
Interest Coverage | — |
Quick Ratio
NRIX
Profitability
|
Metric
|
NRIX
|
|---|---|
Return on Assets (Normalized) | −50.73% |
Return on Equity (Normalized) | −67.29% |
Return on Invested Capital (Normalized) | −63.67% |
Return on Assets
NRIX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|xy>s$@? | LOCK|%?Zw | $128B | |||
| Moderna Inc
MRNA
| LOCK|ymq#>gQ | LOCK|#?t | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@v&^>lF | LOCK|Y$^v | $76B | |||
| argenx SE ADR
ARGX
| LOCK|##!X$K | LOCK|N^P | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&dYwYl | LOCK|Ttg | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?>J<Y@ | LOCK|@^x> | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|yYDr^f#q | LOCK|gc<!F | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|@Z^ww> | LOCK|pm# | $24B | |||
| Incyte Corp
INCY
| LOCK|^dmYXS | LOCK|PQX | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|T$m&TS | LOCK|xx | $15B |
United States